**Socio-economic status**

The socio-economic status (SES) was derived from the postcode of the person and the SES score for that postcode as determined by the Netherlands Institute for Social Research [1]. The SES score is based on the mean income of a postcode where a person lives, the fraction of people with a low income, the fraction of people with low education and the fraction of unemployed people. The SES score is ranked and the national mean is 0 (range−6.65; 3.02). A lower score indicates a lower SES and a higher scores indicates a higher SES.

**Chronic conditions based on Pharmaceutical Cost Groups**

Primary health insurance is compulsory for all Dutch citizens and within the Dutch healthcare system, all insurance companies are obliged to accept citizens applying for primary healthcare insurance.

The healthcare insurance companies receive an equalization contribution from the Healthcare Insurance Fund each year. The amount of the equalization contribution depends on the composition of the insured population. The *Zorginstituut Nederland* (National Institute for Health Care) calculates the equalization contribution per healthcare insurance company [2]. Health insurance companies are by law obligated to periodically supply data to the National Institute for Health Care.

The equalization contribution is calculated based on, among others, the age and gender of the insured population, the nature of income of the insured population (e.g. incapacity benefit, social assistance benefit or paid employment), the socio-economic status of the insured population and the Pharmaceutical Cost Groups (PCGs) of the insured population [2].

PCGs are based on the idea that a patient with a certain chronic condition can be identified by claims known to be prescribed for that chronic condition [3, 4]. An insured person is included into a specific PCG if more than a certain amount (accounting for approximately half a year of use e.g. over 180 defined daily doses) of prescribed drugs has been prescribed during a calendar year. The PCG are classified annually and different ATC codes of one PCG can be combined in order to reach the minimum defined daily doses. A person can have more chronic conditions and thus can be included in multiple PCGs [2].

The Vektis database includes claims for pharmaceutical care, stored in the Pharmacy Information System. This information system contains information on the Anatomical Therapeutic Chemical (ATC) code of the provided drugs, the date the drug was supplied, and the quantity supplied [5]. Appendix tables 1a to 1u describe the ATC codes and the defined daily doses used for the classification of the PCGs. The definition of PCG is maintained by National Institute for Health Care and classification is routinely performed by Vektis [6].

The validity of pharmacy based claims data for the assessment of chronic conditions and prevalence estimates has been demonstrated before in different countries such as The Netherlands, Italy, Switzerland and Canada [4, 7-10]. Databases on prescribed drugs are a valuable source for measuring population’s burden of disease, when clinical data are missing [7].

Variable ‘>=1 new chronic conditions’

We created the dichotomous outcome variable >=1 new chronic conditions. If a person had no chronic condition during 2012, no chronic condition during 2013 and no chronic condition during 2014 then >=1 new chronic conditions was 0. If a person had no chronic condition during 2012, no chronic condition during 2013 and >=1 chronic condition during 2014, then >=1 new chronic conditions was 1.

Variable ‘pre-existing chronic conditions’

Within the logistic regression analyses, having >= 1 chronic conditions before ICU admission was taken into account as possible explanatory variable. We created a dichotomous variable: if a person had no chronic condition during 2012 and no chronic condition during 2013 then pre-existing chronic condition was 0, if a person had >=1 chronic condition during 2012 or >=1 chronic condition during 2013 then pre-existing chronic condition was 1.

**Hospital and non-hospital population**

The hospital population and the non-hospital population are subgroups of the control group and are created based on the Diagnosis Treatment Combinations (DTCs), in Dutch *Diagnose Behandel Combinatie* (DBC).

DTCs are used in the Netherlands for hospital funding. A DTC is defined as all activities and services of hospital and medical specialists originating from the demand for care for which the patient consults the specialist. It covers the complete process of care: from the first consultation of the medical specialist until the completion of the treatment and therefor DTCs cover both outpatient costs and inpatient costs. Apart from these direct costs, indirect costs such as education, research and emergency care are also included [11, 12].

The medical specialist decides on the choice of the DTC to be assigned to a patient upon first contact. The choice for a DTC is made by using a set of guidelines on how to open, close and determine the type of DTC. Every specialty has its own set of instructions, which are updated if necessary. A new DTC is opened when (a) a patient visits a medical specialist for the first time with a new demand for care, (b) when the patient consults a specialist from a different specialty, (c) when a patient is transferred to another provider organization or (d) when a new demand for care arises that will lead to substantially higher costs and effort. A DTC is closed when either the whole treatment has come to an end or after 365 days [11].

DTC maintenance is an independent foundation responsible for adjusting and updating the DBC system. The hospital care providers are obliged to provide their DBC data to the DBC information system [12].

For the hospital population we included all persons which had a DTC declaration starting between 01-01-2013 and 31-12-2013 or a DTC declaration ending between 01-01-2013 and 31-12-2013 and thus had a hospital admission or a consultation with a specialist. The non-hospital population has no DTC declaration starting or ending between 01-01-2013 and 31-12-2013 and thus had no hospital admission during 2013 nor seen a specialist during 2013.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1a. Defined daily doses for asthma** | | | | | | | | | | | | |
| ATC code | Inhalation (aerosol) | | Inhalation (powder) | | Inhalation (solution) | | Oral | | Parenteral | | Rectal | |
| R03AC02 | 0.8 | mg | 0.8 | mg | 10 | mg |  |  |  |  |  |  |
| R03AC03 | 2 | mg | 2 | mg | 20 | mg |  |  |  |  |  |  |
| R03AC12 | 0.1 | mg | 0.1 | mg |  |  |  |  |  |  |  |  |
| R03AC13 | 24 | mcg | 24 | mcg |  |  |  |  |  |  |  |  |
| R03AK06 | 4 | do | 2 | do |  |  |  |  |  |  |  |  |
| R03AK07 | 4 | do | 24 | mcg |  |  |  |  |  |  |  |  |
| R03BA01 | 0.8 | mg | 0.8 | mg | 1.5 | mg |  |  |  |  |  |  |
| R03BA02 | 0.8 | mg | 0.8 | mg | 1.5 | mg |  |  |  |  |  |  |
| R03BA05 | 0.6 | mg | 0.6 | mg | 1.5 | mg |  |  |  |  |  |  |
| R03BA08 | 0.16 | mg |  |  |  |  |  |  |  |  |  |  |
| R03BC01 | 40 | mg | 80 | mg | 80 | mg |  |  |  |  |  |  |
| R03BC03 | 8 | mg |  |  |  |  |  |  |  |  |  |  |
| R03CC02 |  |  |  |  |  |  | 12 | mg | 12 | mg |  |  |
| R03DA04 |  |  |  |  |  |  | 0.4 | g | 0.4 | g | 0.4 | g |
| R03DC03 |  |  |  |  |  |  | 10 | mg |  |  |  |  |
| g: gram  mg: milligram | | mcg: microgram  do: dose | | | | | | | | | | |
| Restriction: only if there is no ATC code for COPD/heavy asthma | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1b. Defined daily doses for COPD/heavy asthma** | | | | | | |  |
| ATC code | Inhalation (aerosol) | | Inhalation (powder) | | Inhalation (solution) | |  |
| R03AC18 |  |  | 150 | mcg |  |  |  |
| R03AK03 | 6 | do | 3 | do |  |  |  |
| R03AK04 | 6 | do |  |  | 7.5 | ml |  |
| R03BB01 | 0.12 | mg | 0.12 | mg | 0.3 | mg |  |
| R03BB04 |  |  | 18 | mcg | 5 | mcg |  |
| mg: milligram  mcg: microgram | | ml: milliliter  do: dose | | | | |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Appendix table 1c. Defined daily doses for Crohn's disease/colitis ulcerosa** | | | | |
| ATC code | Oral | | Rectal | |
| A07EA04 |  |  | 100 | ml |
| A07EA06 | 9 | mg | 1 | tabl |
| A07EC02 | 1.5 | g | 1.5 | g |
| A07EC03 | 1 | g |  |  |
| g: gram  mg: milligram | | ml: milliliter  tabl: tablet | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1d. Defined daily doses for Cystic Fibrosis/pancreas enzymes** | | | | | | |
| ATC code | Inhalation (powder) | | Inhalation (solution) | | Oral | |
| A09AA02 |  |  |  |  | 4-6 | tabl/caps |
| J01GB01 |  |  | 0.3 | g |  |  |
| J01XB01 | 3 | miljU |  |  |  |  |
| R05CB13 |  |  | 2.5 | mg |  |  |
| g: gram  mg: milligram | | miljU: million international unit  tabl/caps: tablet/capsule | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Appendix table 1e. Defined daily doses for depression** | | | | |
| ATC code | Oral | | Parenteral | |
| N06AA02 | 0.1 | g | 0.1 | g |
| N06AA04 | 0.1 | g | 0.1 | g |
| N06AA10 | 75 | mg | 30 | mg |
| N06AA12 | 0.1 | g | 0.1 | g |
| N06AA16 | 0.15 | g |  |  |
| N06AA21 | 0.1 | g | 0.1 | g |
| N06AB03 | 20 | mg |  |  |
| N06AB04 | 20 | mg | 20 | mg |
| N06AB05 | 20 | mg |  |  |
| N06AB06 | 50 | mg |  |  |
| N06AB08 | 0.1 | g |  |  |
| N06AB10 | 10 | mg |  |  |
| N06AF03 | 60 | mg |  |  |
| N06AF04 | 10 | mg |  |  |
| N06AG02 | 0.3 | g |  |  |
| N06AX01 | 50 | mg |  |  |
| N06AX03 | 60 | mg |  |  |
| N06AX05 | 0.3 | g |  |  |
| N06AX11 | 30 | mg |  |  |
| N06AX12 | 0.3 | g\* |  |  |
| N06AX16 | 0.1 | g |  |  |
| N06AX22 | 25 | mg |  |  |
| g: gram  mg: milligram | |  | | |
| Restriction: only if there is no ATC code for Psychoses, Alzheimer’s disease and addictions  \*drugs used to quit smoking excluded | | | | |

|  |  |  |
| --- | --- | --- |
| **Appendix table 1f. Defined daily doses for Diabetes Mellitus type I** | | |
| ATC code | Parenteral | |
| A10AB01 | 40 | IU |
| A10AB04 | 40 | IU |
| A10AB05 | 40 | IU |
| A10AB06 | 40 | IU |
| A10AC01 | 40 | IU |
| A10AD01 | 40 | IU |
| A10AD04 | 40 | IU |
| A10AD05 | 40 | IU |
| A10AE04 | 40 | IU |
| A10AE05 | 40 | IU |
| IU: international unit | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1g. Defined daily doses for Diabetes Mellitus type II** | | | | | | | |
| ATC code | Oral | | Parenteral | | Parenteral depot | | |
| A10BA02 | 2 | g |  |  |  |  |  |
| A10BB01 | 10 | mg |  |  |  |  |  |
| A10BB03 | 1.5 | g |  |  |  |  |  |
| A10BB09 | 60 | mg |  |  |  |  |  |
| A10BB12 | 2 | mg |  |  |  |  |  |
| A10BD02 | 2 | tabl |  |  |  |  |  |
| A10BD03 | 2 | tabl |  |  |  |  |  |
| A10BD04 | 1 | tabl |  |  |  |  |  |
| A10BD05 | 2 | tabl |  |  |  |  |  |
| A10BD07 | 2 | tabl |  |  |  |  |  |
| A10BD08 | 2 | tabl |  |  |  |  |  |
| A10BD11 | 2 | tabl |  |  |  |  |  |
| A10BF01 | 0.3 | g |  |  |  |  |  |
| A10BG02 | 6 | mg |  |  |  |  |  |
| A10BG03 | 30 | mg |  |  |  |  |  |
| A10BH01 | 0.1 | g |  |  |  |  |  |
| A10BH02 | 0.1 | g |  |  |  |  |  |
| A10BH03 | 5 | mg |  |  |  |  |  |
| A10BH05 | 5 | mg\* |  |  |  |  |  |
| A10BX02 | 4 | mg |  |  |  |  |  |
| A10BX04 |  |  | 15 | mcg | 286 | mcg\* |  |
| A10BX07 |  |  | 1.2 | mg |  |  |  |
| g: gram  mg: milligram | | mcg: microgram  tabl: tablet | | | | | |
| Restriction: Only if there is no ATC code for DM type I  \* Added by the WHO since 01-01-2013 | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Appendix table 1h. Defined daily doses for diseases of the central neurological system** | | | | | |
| ATC-code | Oral | | | Parenteral | |
| L03AB07 |  |  | | 4.3 | mcg |
| L03AB08 |  |  | | 4 | miljU |
| L03AX13 |  |  | | 20 | mg |
| L04AA27 | 0.5 | mg | |  |  |
| M03BX01 | 50 | mg | | 0.55 | mg |
| M03BX02 | 12 | mg | |  |  |
| N07XX02 | 0.1 | g | |  |  |
| N07XX08 |  |  | | 20 | mg |
| g: gram  mg: milligram | | | mcg: microgram  miljU: million international unit | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1i. Defined daily doses for epilepsy** | | | | | | |
| ATC-code | Oral | | Parenteral | | Rectal | |
| N03AA02 | 0.1 | g | 0.1 | g |  |  |
| N03AA03 | 1.25 | g |  |  |  |  |
| N03AB02 | 0.3 | g | 0.3 | g |  |  |
| N03AD01 | 1.25 | g |  |  |  |  |
| N03AE01 | 8 | mg | 8 | mg |  |  |
| N03AF01 | 1 | g |  |  | 1 | g |
| N03AF02 | 1 | g |  |  |  |  |
| N03AF03 | 1.4 | g |  |  |  |  |
| N03AG01 | 1.5 | g | 1.5 | g | 1.5 | g |
| N03AG04 | 2 | g |  |  |  |  |
| N03AX03 | 0.4 | g |  |  |  |  |
| N03AX09 | 0.3 | g |  |  |  |  |
| N03AX10 | 2.4 | g |  |  |  |  |
| N03AX11 | 0.3 | g |  |  |  |  |
| N03AX14 | 1.5 | g | 1.5 | g |  |  |
| N03AX15 | 0.2 | g |  |  |  |  |
| N03AX17 | 1 | g |  |  |  |  |
| N03AX18 | 0.3 | g | 0.3 | g |  |  |
| N03AX21 | 0.9 | g\* |  |  |  |  |
| N05BA09 | 20 | mg |  |  |  |  |
| g: gram  mg: milligram | |  | | | | |
| \* Added by the WHO since 01-01-2013 | | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1j. Defined daily doses for glaucoma** | | | | | | |
| ATC-code | Oral | | Parenteral | | Ocular | |
| S01EA02 |  |  |  |  | 0.2 | ml |
| S01EA03 |  |  |  |  | 0.3 | ml |
| S01EA05 |  |  |  |  | 0.2 | ml |
| S01EB01 |  |  |  |  | 0.4/40 | ml/mg |
| S01EC01 | 0.75 | g | 0.75 | g |  |  |
| S01EC03 |  |  |  |  | 0.3 | ml |
| S01EC04 |  |  |  |  | 0.2 | ml |
| S01ED01 |  |  |  |  | 0.2 | ml |
| S01ED02 |  |  |  |  | 0.2 | ml |
| S01ED03 |  |  |  |  | 0.2 | ml |
| S01ED04 |  |  |  |  | 0.2 | ml |
| S01ED05 |  |  |  |  | 0.2 | ml |
| S01ED51 |  |  |  |  | 0.1/0.2 | ml |
| S01ED54 |  |  |  |  | 0.3 | ml |
| S01EE01 |  |  |  |  | 0.1 | ml |
| S01EE03 |  |  |  |  | 0.1 | ml |
| S01EE04 |  |  |  |  | 0.1 | ml |
| S01EE05 |  |  |  |  | 0.3 | ml |
| mg: milligram | | ml: milliliter | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1k. Defined daily doses for heart diseases** | | | | | | | | | | |
| ATC-code | Oral | | Oral (aerosol) | | Parenteral | | Sublingual | | Transdermal | |
| C01AA05 | 0.25 | mg |  |  | 0.25 | mg |  |  |  |  |
| C01BA01 | 1.2 | g |  |  |  |  |  |  |  |  |
| C01BA03 | 0.4 | mg |  |  | 0.4 | mg |  |  |  |  |
| C01BB01 |  |  |  |  | 3 | g |  |  |  |  |
| C01BC03 | 0.3 | g |  |  | 0.3 | g |  |  |  |  |
| C01BC04 | 0.2 | g |  |  | 0.2 | g |  |  |  |  |
| C01BD01 | 0.2 | g |  |  | 0.2 | g |  |  |  |  |
| C01CA16 | 0.3 | g |  |  |  |  |  |  |  |  |
| C01CE02 |  |  |  |  | 50 | mg |  |  |  |  |
| C01CE03 |  |  |  |  | 1 | g |  |  |  |  |
| C01DA02 | 5 | mg | 2.5 | mg | 10 | mg | 2.5 | mg | 5 | mg |
| C01DA08 | 60 | mg | 20 | mg | 10 | mg | 20 | mg | 0.1 | g |
| C01DA14 | 40 | mg |  |  |  |  |  |  |  |  |
| C01DX16 | 40 | mg |  |  |  |  |  |  |  |  |
| C01EB17 | 10 | mg |  |  |  |  |  |  |  |  |
| C03CA01 | 40 | mg |  |  | 40 | mg |  |  |  |  |
| C03CA02 | 1 | mg |  |  | 1 | mg |  |  |  |  |
| g: gram  mg: milligram | |  | | | | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Appendix table 1l. Defined daily doses for high cholesterol** | | | | |
| ATC code | Oral | | Parenteral | |
| C04AD02 | 0.9 | g | 0.9 | g |
| C10AA01 | 30 | mg |  |  |
| C10AA03 | 30 | mg |  |  |
| C10AA04 | 60 | mg |  |  |
| C10AA05 | 20 | mg |  |  |
| C10AA07 | 10 | mg |  |  |
| C10AB02 | 0.6 | g |  |  |
| C10AB04 | 1.2 | g |  |  |
| C10AB08 | 0.1 | g |  |  |
| C10AC01 | 14 | g |  |  |
| C10AC04 | 3.75 | g |  |  |
| C10AD02 | 2 | g |  |  |
| C10AD06 | 0.5 | g |  |  |
| C10AX09 | 10 | mg |  |  |
| C10BA02 | 1 | tabl |  |  |
| g: gram  mg: milligram | | tabl: tablet | | |
| Restriction:only if there is no ATC code for heart diseases, DM type I or DM type II | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Appendix table 1m. Defined daily doses for HIV/AIDS** | | | | | |
| ATC-code | Oral | | | Parenteral | |
| J05AB06 | 3 | g | | 0.5 | g |
| J05AB14 | 0.9 | g | |  |  |
| J05AD01 |  |  | | 6.5 | g |
| J05AE01 | 1.8 | g | |  |  |
| J05AE02 | 2.4 | g | |  |  |
| J05AE03 | 1.2 | g | |  |  |
| J05AE04 | 2.25 | g | |  |  |
| J05AE06 | 0.8 | g | |  |  |
| J05AE07 | 1.4 | g | |  |  |
| J05AE08 | 0.3 | g | |  |  |
| J05AE09 | 1 | g | |  |  |
| J05AE10 | 1.2 | g | |  |  |
| J05AF01 | 0.6 | g | | 0.6 | g |
| J05AF02 | 0.4 | g | |  |  |
| J05AF04 | 80 | mg | |  |  |
| J05AF05 | 0.3 | g | |  |  |
| J05AF06 | 0.6 | g | |  |  |
| J05AF07 | 0.245 | g | |  |  |
| J05AF09 | 0.2 | g | |  |  |
| J05AG01 | 0.4 | g | |  |  |
| J05AG03 | 0.6 | g | |  |  |
| J05AG04 | 0.4 | g | |  |  |
| J05AG05 | 25 | mg | |  |  |
| J05AR01 | 2 | tabl | |  |  |
| J05AR02 | 1 | tabl | |  |  |
| J05AR03 | 1 | tabl | |  |  |
| J05AR04 | 2 | tabl | |  |  |
| J05AR06 | 1 | tabl | |  |  |
| J05AR08 | 1 | tabl | |  |  |
| J05AX07 |  |  | | 0.18 | g |
| J05AX08 | 0.8 | g | |  |  |
| J05AX09 | 0.6 | g | |  |  |
| g: gram  mg: milligram | | | tabl: tablet | | |
| \* Added by the WHO since 01-01-2013 | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1n. Defined daily doses for hormone sensitive tumours** | | | | | | | | | | |
| ATC-code | Oral | | Parenteral | | Parenteral depot | | Nasal | | Implantation | |
| H01CA03 |  |  |  |  |  |  |  |  | 0.137 | mg |
| H01CB05 |  |  | 1.2 | mg |  |  |  |  |  |  |
| L02AB01 | 0.16 | g |  |  |  |  |  |  |  |  |
| L02AB02 | 1 | g | 1 | g |  |  |  |  |  |  |
| L02AE01 |  |  | 1.5 | mg |  |  | 1.2 | mg | 0.11 | mg |
| L02AE02 |  |  | 1 | mg | 0.134 | mg |  |  |  |  |
| L02AE03 |  |  |  |  |  |  |  |  | 0.129 | mg |
| L02BA01 | 20 | mg |  |  |  |  |  |  |  |  |
| L02BA03 |  |  | 8.3 | mg |  |  |  |  |  |  |
| L02BB01 | 0.75 | g |  |  |  |  |  |  |  |  |
| L02BB02 | 0.3 | g |  |  |  |  |  |  |  |  |
| L02BB03 | 50 | mg |  |  |  |  |  |  |  |  |
| L02BG03 | 1 | mg |  |  |  |  |  |  |  |  |
| L02BG04 | 2.5 | mg |  |  |  |  |  |  |  |  |
| L02BG06 | 25 | mg |  |  |  |  |  |  |  |  |
| L02BX01 |  |  | 3.571 | mg |  |  |  |  |  |  |
| L02BX02 |  |  | 2.7 | mg |  |  |  |  |  |  |
| g: gram  mg: milligram | |  | | | | | | | | |
| Restriction: Only if there is no ATC code for cancer | | | | | | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1o. Defined daily doses for kidney diseases** | | | | | | | |
| ATC-code | Oral | | | Parenteral | | | |
| B03XA01 |  |  | | 1000 | IU | | |
| B03XA02 |  |  | | 4.5 | mcg | | |
| B03XA03 |  |  | | 4 | mcg | | |
| V03AE01 | 45 | mg | |  |  | | |
| V03AE02 | 6.4 | g | |  |  | | |
| V03AE03 | 2.25 | g | |  |  | | |
| V03AE04 | 6 | tabl | |  |  | | |
| g: gram  mg: milligram  mcg: microgram | | tabl: tablet  IU: international Unit | | | | | |
| **Appendix table 1p. Defined daily doses for neuropathic pains** | | | | | | | |
| ATC-code | Oral | | | Parenteral | | Transdermal | |
| N01BX04 |  |  | |  |  | 4 | g |
| N03AX12 | 1.8 | g | |  |  |  |  |
| N03AX16 | 0.3 | g | |  |  |  |  |
| N06AA09 | 75 | mg | | 75 | mg |  |  |
| N06AX21 | 60 | mg | |  |  |  |  |
| g: gram  mg: milligram | | |  | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1q. Defined daily doses for Parkinson’s disease** | | | | | | |
| ATC-code | Oral | | Parenteral | | Transdermal | |
| N04BA02 | 0.6 | g |  |  |  |  |
| N04BA03 | 0.45 | g |  |  |  |  |
| N04BB01 | 0.2 | g |  |  |  |  |
| N04BC01 | 40 | mg |  |  |  |  |
| N04BC02 | 3 | mg |  |  |  |  |
| N04BC04 | 6 | mg |  |  |  |  |
| N04BC05 | 2.5 | mg |  |  |  |  |
| N04BC07 |  |  | 20 | mg |  |  |
| N04BC09 |  |  |  |  | 6 | mg |
| N04BD01 | 5 | mg |  |  |  |  |
| N04BD02 | 1 | mg |  |  |  |  |
| N04BX01 | 0.45 | g |  |  |  |  |
| N04BX02 | 1 | g |  |  |  |  |
| g: gram  mg: milligram | |  | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1r. Defined daily doses for psychoses, Alzheimer’s disease and addictions** | | | | | | | | | | | | |
| ATC-code | Oral | | Parenteral | | Parenteral depot | | Rectal | | Transdermal | | Sublingual | |
| N05AA01 | 0.3 | g | 0.1 | g |  |  | 0.3 | g |  |  |  |  |
| N05AB02 | 10 | mg | 1 | mg |  |  |  |  |  |  |  |  |
| N05AB03 | 30 | mg | 10 | mg | 7 | mg | 16 | mg |  |  |  |  |
| N05AC01 | 50 | mg | 20 | mg |  |  |  |  |  |  |  |  |
| N05AD01 | 8 | mg | 8 | mg | 3.3 | mg |  |  |  |  |  |  |
| N05AD05 | 0.2 | g |  |  |  |  |  |  |  |  |  |  |
| N05AD06 | 10 | mg | 10 | mg | 3.3 | mg |  |  |  |  |  |  |
| N05AE03 | 16 | mg |  |  |  |  |  |  |  |  |  |  |
| N05AF01 | 6 | mg | 4 | mg |  |  |  |  |  |  |  |  |
| N05AF03 | 0.3 | g | 50 | mg |  |  |  |  |  |  |  |  |
| N05AF05 | 30 | mg | 30 | mg | 15 | mg |  |  |  |  |  |  |
| N05AG01 |  |  | 0.7 | mg |  |  |  |  |  |  |  |  |
| N05AG02 | 4 | mg |  |  |  |  |  |  |  |  |  |  |
| N05AG03 | 6 | mg |  |  |  |  |  |  |  |  |  |  |
| N05AH02 | 0.3 | g | 0.3 | g |  |  |  |  |  |  |  |  |
| N05AH03 | 10 | mg | 10 | mg | 10 | mg |  |  |  |  |  |  |
| N05AH04 | 0.4 | g |  |  |  |  |  |  |  |  |  |  |
| N05AL01 | 0.8 | g | 0.8 | g |  |  |  |  |  |  |  |  |
| N05AX08 | 5 | mg |  |  | 2.7 | mg |  |  |  |  |  |  |
| N05AX12 | 15 | mg | 15 | mg |  |  |  |  |  |  |  |  |
| N05AX13 | 6 | mg |  |  | 2.5 | mg |  |  |  |  |  |  |
| N06DA03 | 9 | mg |  |  |  |  |  |  | 9.5 | mg |  |  |
| N06DA04 | 16 | mg |  |  |  |  |  |  |  |  |  |  |
| N06DX01 | 20 | mg |  |  |  |  |  |  |  |  |  |  |
| N07BB01 | 0.2 | g |  |  |  |  |  |  |  |  |  |  |
| N07BB03 | 2 | g |  |  |  |  |  |  |  |  |  |  |
| N07BB04 | 50 | mg |  |  |  |  |  |  |  |  |  |  |
| N07BC01 |  |  |  |  |  |  |  |  |  |  | 8 | mg |
| N07BC02 | 25 | mg | 25 | mg |  |  |  |  |  |  |  |  |
| N07BC51 |  |  |  |  |  |  |  |  |  |  | 8 | mg |
| g: gram  mg: milligram | |  | | | | | | | | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Appendix table 1s. Defined daily doses for rheumatism** | | | | | | | |
| ATC-code | Oral | | | Parenteral | | Rectal | |
| A07EC01 | 2 | g | |  |  | 2 | g |
| L01BA01 |  |  | | 3.571 | mg |  |  |
| L04AA13 | 20 | mg | |  |  |  |  |
| L04AX03 | 2.5 | mg | |  |  |  |  |
| M01CB01 |  |  | | 2.4 | mg |  |  |
| M01CC01 | 0.5 | g | |  |  |  |  |
| P01BA02 | 0.516 | g | |  |  |  |  |
| g: gram  mg: milligram | | |  | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Appendix table 1t. Defined daily doses for thyroid diseases** | | | | |
| ATC-code | Oral | | Parenteral | |
| H03AA01 | 0.15 | mg | 0.15 | mg |
| H03AA02 | 60 | mcg | 60 | mcg |
| H03BA02 | 0.1 | g |  |  |
| H03BB01 | 15 | mg |  |  |
| H03BB02 | 10 | mg |  |  |
| g: gram  mg: milligram | | mcg: microgram | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Appendix table 1u. Defined daily doses for transplantations** | | | | | |
| ATC-code | Oral | | | Parenteral | |
| L04AA06 | 2 | g | | 2 | g |
| L04AA10 | 3 | mg | |  |  |
| L04AA18 | 1.5 | mg | |  |  |
| L04AD01 | 0.25 | g | | 0.25 | g |
| L04AD02 | 5 | mg | | 5 | mg |
| L04AX01 | 0.15 | g | | 0.15 | g |
| g: gram  mg: milligram | | |  | | |

**References**

1. Knol F. Van hoog naar laag; van laag naar hoog. Den Haag: Sociaal en Cultureel Planbureau / Elsevier Bedrijfsinformatie; 1998.

2. Zorginstituut Nederland. In: Wat is risicoverevening? https://[www.zorginstituutnederland.nl/financiering/risicoverevening-zvw/wat-is-risicoverevening](http://www.zorginstituutnederland.nl/financiering/risicoverevening-zvw/wat-is-risicoverevening). Accessed 10.06.2018.

3. Lamers LM. Pharmacy costs groups: a risk-adjuster for capitation payments based on the use of prescribed drugs. Med Care. 1999;37:8.

4. Lamers LM, van Vliet RC. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004;68:1.

5. WHO Collaborating Centre for Drug Statistics Methodology. https://[www.whocc.no/](http://www.whocc.no/). Accessed 10.6.2018.

6. National Health Care Institute. https://english.zorginstituutnederland.nl. Accessed 08.11.2016.

7. Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health. 2013;13.

8. Maio V, Yuen E, Rabinowitz C, Louis D, Jimbo M, Donatini A et al. Using pharmacy data to identify those with chronic conditions in Emilia Romagna, Italy. J Health Serv Res Policy. 2005;10:4.

9. Chini F, Pezzotti P, Orzella L, Borgia P, Guasticchi G. Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC Public Health. 2011;11.

10. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:8.

11. Hasaart F. Incentives in the Diagnosis Treatment Combination payment system for specialist medical care. A study about behavioral responses of medical specialists and hospitals in the Netherlands.: University of Maastricht; 2011.

12. Schafer W, Kroneman M, Boerma W, van den Berg M, Westert G, Deville W et al. The Netherlands: health system review. Health Syst Transit. 2010;12:1.